-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

-The Hindu Considering the knowledge of English as a mark of social advancement and that of the vernacular as backwardness disenfranchises significant sections of society In a village in Ghazipur district that borders Varanasi, there is a young man who teaches English and "personality development" to the sons and daughters of local shopkeepers, farmers and truck drivers. The classes are held from 6 to 8 in the morning and again in the...

-Reuters WASHINGTON: World Bank President Jim Yong Kim called for a commitment by the international community on Tuesday to end extreme poverty by 2030 and to improve the lives of the most vulnerable people living in developing countries. To reach that goal, Kim said the world need to reduce the number of people living below the poverty line of $1.25 per day to 3 percent globally by 2030, and raise the per...

-The Hindu The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug. A Bench of Justices Aftab Alam and Ranjana Desai said, "We certainly do not wish the law of patent... to develop on the lines where there may be a vast...

-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...